Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 2Phase 3 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × iberdomide × 30 days × Clear all
NCT06465316 2026-05-27

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Recruiting
26 enrolled
Plasma cell

Multiple Myeloma

NCT06215118 2026-05-22

MagnetisMM-30

Pfizer

Phase 1 Recruiting
87 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Recruiting
121 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡